Hernández-Ordóñez SO

Language: Spanish
References: 25
Page: 90-96
PDF size: 170.76 Kb.

ABSTRACT

The nephrotic syndrome is a frequent clinical condition and diabetic nephropathy the most common cause. In non diabetic population primary glomerular diseases (minimal change disease, IgA nephropathy, membranous glomerulopathy, focal segmental glomerulosclerosis, etc.) are responsible for the nephrotic syndrome and it’s frequency depends on the age at presentation. The diagnostic approach includes a renal biopsy which guides the specific therapy in almost all cases of primary glomerular diseases. Symptomatic treatment is focused on each component of the nephrotic syndrome: edema, dyslipidemia, and proteinuria.

REFERENCES

1. Orth SR, Ritz E. The nephrotic syndrome. N Engl J Med 1998; 338(17): 1202-1211.

2. Waller KV, Ward KM, Mahan JD, Wismatt DK. Current concepts in proteinuria. Clin Chem 1989; 35(5): 755-765.

3. Feehally J, Floege J, Johnson R. Comprehensive Clinical Nephrology. Philadelphia, Mosby Elsevier. 2007.

4. Kaysen GA, Gambertoglio J, Felts J, Hutchison FN. Albumin synthesis, albuminuria and hyperlipemia in nephrotic patients. Kidney Int 1987; 31(6): 1368-1376.

5. Venkat KK. Proteinuria and microalbuminuria in adults: significance, evaluation, and treatment. South Med J 2004; 97(10): 969-979.

6. Haraldsson B, Nyström J, Deen WM. Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev 2008; 88(2): 451-487.

7. Rose BD, Post TW. Clinical physiology of acid–base and electrolyte disorders. New York. McGraw–Hill. 2001.

8. Yamauchi A, Fukuhara Y, Yamamoto S, Yano F, Takenaka M, Imai E, Noguchi T, Tanaka T, Kamada T, Ueda N. Oncotic pressure regulates gene transcriptions of albumin and apolipoprotein B in cultured rat hepatoma cells. Am J Physiol 1992; 263(2 Pt 1): C397-404.

9. Trevisan R, Dodesini AR, Lepore G. Lipids and renal disease. J Am Soc Nephrol 2006; 17(4 Suppl 2): S145-7.

10. Ordónez JD, Hiatt RA, Killebrew EJ, Fireman BH. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 1993; 44: 638-642.

11. Rabelink TJ, Zwaginga JJ, Koomans HA, Sixma JJ. Thrombosis and hemostasis in renal disease. Kidney Int 1994; 46(2): 287-296.

12. Glassock RJ. Prophylactic anticoagulation in nephrotic syndrome: a clinical conundrum. J Am Soc Nephrol 2007; 18(8): 2221-2225.

13. Ponticelli C. Membranous nephropathy. J Nephrol 2007; 20(3): 268-287.

14. Braden GL, Mulhern JG, O’Shea MH, Nash SV, Ucci AA Jr, Germain MJ. Changing incidence of glomerular diseases in adults. Am J Kidney Dis 2000; 35(5): 878-883.

15. Rivera F, López-Gómez JM, Pérez-García R. Spanish registry of glomerulonephritis. Frequency of renal pathology in Spain 1994-1999. Nephrol Dial Transplant 2002; 17(9): 1594-1602.

16. Schena FP. Survey of the Italian registry of renal biopsies. Frequency of the renal diseases for 7 consecutive years. The Italian Group of Renal Immunopathology. Nephrol Dial Transplant 1997; 12(3): 418-426.

17. Swaminathan S, Leung N, Lager DJ, Melton LJ 3rd, Bergstralh EJ, Rohlinger A, Fervenza FC. Changing incidence of glomerular disease in Olmsted County, Minnesota: a 30-year renal biopsy study. Clin J Am Soc Nephrol 2006; 1(3): 483-487.

18. Xin G, Wang M, Jiao LL, Xu GB, Wang HY. Protein-to-creatinine ratio in spot urine samples as a predictor of quantitation of proteinuria. Clin Chim Acta 2004; 350(1-2): 35-39.

19. Shidham G, Hebert LA. Timed urine collections are not needed to measure urine protein excretion in clinical practice. Am J Kidney Dis 2006; 47(1): 8-14.

20. Wilmer WA, Rovin BH, Hebert CJ, Rao SV, Kumor K, Hebert LA. Management of glomerular proteinuria: A commentary. J Am Soc Nephrol 2003; 14(12): 3217-3232.

21. Fogo AB. Approach to renal biopsy. Am J Kidney Dis 2003; 42(4): 826-836.

22. Expert panel on detection evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486-2497.

23. Fernández-Juárez G, Barrio V, de Vinuesa SG, Goicoechea M, Praga M, Luño J. Dual blockade of the renin-angiotensin system in the progression of renal disease: the need for more clinical trials. J Am Soc Nephrol 2006; 17(12 Suppl 3): S250-4.

24. National Kidney Foundation. NKF – KDOQI Guidelines. http://www.kidney.org/professionals/KDOQI/guidelines_ckd/toc.htm

25. Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 2006; 1(2): 256-262.